| MeSH term | MeSH ID | Detail |
|---|---|---|
| Prosthesis-Related Infections | D016459 | 7 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Tooth Discoloration | D014075 | 7 associated lipids |
| Sinusitis | D012852 | 9 associated lipids |
| Fusobacterium Infections | D005674 | 3 associated lipids |
| Enterocolitis, Pseudomembranous | D004761 | 8 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Pseudomonas Infections | D011552 | 25 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| van Duijkeren E et al. | Human-to-dog transmission of methicillin-resistant Staphylococcus aureus. | 2004 | Emerging Infect. Dis. | pmid:15663871 |
| Giamarellos-Bourboulis EJ et al. | Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. | 2005 | Int. J. Antimicrob. Agents | pmid:15664488 |
| Kunicki PK and Sobieszczańska-Małek M | Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. | 2005 | Ther Drug Monit | pmid:15665756 |
| Malfatti F et al. | Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. | 2005 | Med. Sci. Monit. | pmid:15668640 |
| Berg HF et al. | Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. | 2005 | Clin. Infect. Dis. | pmid:15668857 |
| Schuster M | [Helicobacter pylori: reasons for eradication]. | 2004 | Praxis (Bern 1994) | pmid:15672764 |
| Canbaz S et al. | Survey of general practitioners' knowledge about Helicobacter pylori infection. | 2005 | BMC Gastroenterol | pmid:15673470 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Smith ID et al. | Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland. | 2005 | Eur J Gastroenterol Hepatol | pmid:15674093 |
| Altunaiji S et al. | Antibiotics for whooping cough (pertussis). | 2005 | Cochrane Database Syst Rev | pmid:15674946 |
| Yamaguchi K et al. | Clarithromycin reduces prednisolone requirements for treatment of intractable Takayasu arteritis. | 2004 | Clin. Exp. Rheumatol. | pmid:15675144 |
| Kania RE et al. | Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the larynx. | 2005 | Head Neck | pmid:15678477 |
| Kushibe K et al. | [Lung resections for lung cancer with idiopathic pulmonary fibrosis]. | 2005 | Kyobu Geka | pmid:15678962 |
| Aydemir S et al. | Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15682477 |
| Amini H and Ahmadiani A | Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. | 2005 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:15686985 |
| Sheu BS et al. | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 2005 | Aliment. Pharmacol. Ther. | pmid:15691303 |
| Watanabe K et al. | Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003. | 2005 | Helicobacter | pmid:15691310 |
| Marko D et al. | Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. | 2005 | Helicobacter | pmid:15691312 |
| Kato S et al. | Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature. | 2005 | J. Gastroenterol. | pmid:15692795 |
| Molden E et al. | Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. | 2005 | Eur. J. Clin. Pharmacol. | pmid:15692832 |
| de Silva HA et al. | Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study. | 2004 | Ceylon Med J | pmid:15693450 |
| Can F et al. | [Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens]. | 2004 | Mikrobiyol Bul | pmid:15700660 |
| Ma HL et al. | [Polarographic catalytic wave of clarithromycin and its applications]. | 2004 | Yao Xue Xue Bao | pmid:15700824 |
| Fouda SI et al. | Beta-lactam and macrolide resistance and serotype distribution among Streptococcus pneumoniae isolates from Saudi Arabia. | 2004 | J Chemother | pmid:15700841 |
| Cifaldi MA | Comments on: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. | 2004 | Curr Med Res Opin | pmid:15701207 |
| Toracchio S et al. | Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. | 2005 | Dig Liver Dis | pmid:15702857 |
| Gerónimo-Pardo M et al. | Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. | 2005 | Ann Pharmacother | pmid:15703161 |
| Yoshimura K et al. | [A case of pulmonary infection due to Mycobacterium simiae]. | 2005 | Nihon Kokyuki Gakkai Zasshi | pmid:15704450 |
| Hirata S et al. | Interactions between clarithromycin and digoxin in patients with end-stage renal disease. | 2005 | Int J Clin Pharmacol Ther | pmid:15704612 |
| Bruijnesteijn van Coppenraet LE et al. | Mycobacterium haemophilum and lymphadenitis in children. | 2005 | Emerging Infect. Dis. | pmid:15705324 |
| Boivin G et al. | Human parechovirus 3 and neonatal infections. | 2005 | Emerging Infect. Dis. | pmid:15705330 |
| Molteni C et al. | Mycobacterium lentiflavum infection in immunocompetent patient. | 2005 | Emerging Infect. Dis. | pmid:15705334 |
| Bele M et al. | Silica coatings on clarithromycin. | 2005 | Int J Pharm | pmid:15707741 |
| Okudaira K et al. | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. | 2005 | Aliment. Pharmacol. Ther. | pmid:15710002 |
| Tozzi AE et al. | Diagnosis and management of pertussis. | 2005 | CMAJ | pmid:15710944 |
| Liang J et al. | [Analysis of the key intermediates for the regioselectivity control in the methylation of the manufacture of clarithromycin by reversed-phase high performance liquid chromatography]. | 2004 | Se Pu | pmid:15712906 |
| Tanaka J et al. | Influence of antimicrobial treatment for Helicobacter pylori infection on the intestinal microflora in Japanese macaques. | 2005 | J. Med. Microbiol. | pmid:15713617 |
| Banerjee D et al. | The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. | 2005 | Respir Med | pmid:15715188 |
| Candelli M et al. | Treatment of H. pylori infection: a review. | 2005 | Curr. Med. Chem. | pmid:15720247 |
| Salem II et al. | Liposome-encapsulated antibiotics. | 2005 | Meth. Enzymol. | pmid:15721386 |
| Srinivasan R and Yeo TH | Are newer macrolides effective in eradicating carriage of pertussis? | 2005 | Arch. Dis. Child. | pmid:15723933 |
| Swanson RN et al. | Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. | 2005 | Treat Respir Med | pmid:15725048 |
| Hotomi M et al. | Current status of antimicrobial susceptibility of clinical isolates of Streptococcus pyogenes in Japan: report of a countrywide surveillance study. | 2005 | J. Infect. Chemother. | pmid:15729489 |
| Hess CL et al. | Mycobacterium marinum infections of the upper extremity. | 2005 | Plast. Reconstr. Surg. | pmid:15731663 |
| Inaba T et al. | Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. | 2005 | Eur. J. Clin. Invest. | pmid:15733077 |
| Yang H et al. | [Macrolide-resistant Streptococcus pneumoniae in the pediatric population in Beijing]. | 2004 | Zhonghua Er Ke Za Zhi | pmid:15733368 |
| Magistà AM et al. | Helicobacter pylori status and symptom assessment two years after eradication in pediatric patients from a high prevalence area. | 2005 | J. Pediatr. Gastroenterol. Nutr. | pmid:15735485 |
| Pinto AG et al. | Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. | 2005 | Clin. Pharmacol. Ther. | pmid:15735612 |
| Mykietiuk A et al. | Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. | 2005 | Clin. Infect. Dis. | pmid:15736010 |
| Ohara T et al. | Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. | 2004 Nov-Dec | Anticancer Res. | pmid:15736403 |
| Sanz Santaeufemia FJ et al. | [Usefulness of chemotherapy associated with surgery in the management of nontuberculous mycobacterial adenitis]. | 2005 | An Pediatr (Barc) | pmid:15737291 |
| Kadota J et al. | Antibiotic-induced apoptosis in human activated peripheral lymphocytes. | 2005 | Int. J. Antimicrob. Agents | pmid:15737515 |
| RodrÃguez JC et al. | Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration. | 2005 | Int. J. Antimicrob. Agents | pmid:15737516 |
| de Mascarel A et al. | Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. | 2005 | Virchows Arch. | pmid:15742170 |
| Chang CC et al. | Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils. | 2005 | World J. Gastroenterol. | pmid:15742400 |
| Feng LY et al. | Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. | 2005 | World J. Gastroenterol. | pmid:15742421 |
| Amsden GW | Treatment of Legionnaires' disease. | 2005 | Drugs | pmid:15748096 |
| Berg HF et al. | Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. | 2005 | J. Clin. Microbiol. | pmid:15750103 |
| Saito M et al. | Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. | 2005 | Br J Clin Pharmacol | pmid:15752376 |
| Sethi S et al. | Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. | 2005 | Ann. Clin. Microbiol. Antimicrob. | pmid:15755326 |
| Scholze A et al. | Cutaneous Mycobacterium abscessus infection after kidney transplantation. | 2005 | Nephrol. Dial. Transplant. | pmid:15755761 |
| Saad R and Chey WD | A clinician's guide to managing Helicobacter pylori infection. | 2005 | Cleve Clin J Med | pmid:15757167 |
| Radzikowska E et al. | [Organizing pneumonia--analysis of 18 own cases]. | 2004 | Pneumonol Alergol Pol | pmid:15757271 |
| Kandula VR et al. | Tipranavir: a novel second-generation nonpeptidic protease inhibitor. | 2005 | Expert Rev Anti Infect Ther | pmid:15757454 |
| MacDougall C et al. | Antimicrobial drug prescribing for pneumonia in ambulatory care. | 2005 | Emerging Infect. Dis. | pmid:15757551 |
| Stelzmueller I et al. | Mycobacterium chelonae skin infection in kidney-pancreas recipient. | 2005 | Emerging Infect. Dis. | pmid:15759344 |
| Rimbara E et al. | Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. | 2005 | Clin. Microbiol. Infect. | pmid:15760428 |
| Zhou S et al. | Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. | 2005 | Clin Pharmacokinet | pmid:15762770 |
| Giamarellos-Bourboulis E et al. | Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. | 2005 | Scand. J. Infect. Dis. | pmid:15764190 |
| Ladrón de Guevara L et al. | [Evaluation of the symptomatology and quality of life in functional dyspepsia before and after Helicobacter pylori eradication treatment]. | 2004 Oct-Dec | Rev Gastroenterol Mex | pmid:15765971 |
| Koivisto TT et al. | First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. | 2005 | Aliment. Pharmacol. Ther. | pmid:15771764 |
| Halpern MT et al. | Meta-analysis of bacterial resistance to macrolides. | 2005 | J. Antimicrob. Chemother. | pmid:15772147 |
| Bhattacharya S et al. | Fusobacteriosis presenting as community acquired pneumonia. | 2005 | J. Infect. | pmid:15780418 |
| GarcÃa Vázquez E et al. | Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. | 2005 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:15782278 |
| Kurashima A | [Clinical study on development of nontuberculous mycobacterial lung disease]. | 2004 | Kekkaku | pmid:15782619 |
| Stout JE et al. | Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. | 2005 | Int. J. Antimicrob. Agents | pmid:15784309 |
| Isomoto H et al. | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15786539 |
| Wang HH et al. | One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. | 2005 | World J. Gastroenterol. | pmid:15786549 |
| Chatterjee A et al. | Antimicrobial effects of antioxidants with and without clarithromycin on Helicobacter pylori. | 2005 | Mol. Cell. Biochem. | pmid:15792361 |
| Shi J et al. | Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. | 2005 | Int J Clin Pharmacol Ther | pmid:15792396 |
| Falzari K et al. | In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. | 2005 | Antimicrob. Agents Chemother. | pmid:15793125 |
| Lee JH et al. | Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. | 2005 | Antimicrob. Agents Chemother. | pmid:15793150 |
| Pfister P et al. | 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G. | 2005 | Proc. Natl. Acad. Sci. U.S.A. | pmid:15795375 |
| Terano A | [Diagnosis of and therapy for peptic ulcer]. | 2005 | Nippon Naika Gakkai Zasshi | pmid:15796055 |
| Ruiz GarcÃa A et al. | [Effect of the Helicobacter pylori eradication in patients with functional dyspepsia: randomised placebo-controlled trial]. | 2005 | Med Clin (Barc) | pmid:15799844 |
| Ishiga T et al. | [A case of Kartagener's syndrome]. | 2005 | Nihon Kokyuki Gakkai Zasshi | pmid:15801284 |
| Gotfried M et al. | Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. | 2005 | Curr Med Res Opin | pmid:15801995 |
| Skrepnek GH et al. | An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. | 2005 | Curr Med Res Opin | pmid:15801997 |
| Heifets L et al. | Capreomycin is active against non-replicating M. tuberculosis. | 2005 | Ann. Clin. Microbiol. Antimicrob. | pmid:15804353 |
| Peters TS | Do preclinical testing strategies help predict human hepatotoxic potentials? | 2005 | Toxicol Pathol | pmid:15805066 |
| Kobashi Y et al. | Chronic necrotizing pulmonary aspergillosis complicated by a cavitary lesion caused by Pulmonary Mycobacterium-avium complex disease. | 2005 | Intern. Med. | pmid:15805716 |
| Sakai T et al. | Mycobacterium peregrinum infection in a patient with AIDS. | 2005 | Intern. Med. | pmid:15805720 |
| Stasi R et al. | Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. | 2005 | Am. J. Med. | pmid:15808140 |
| Manes G et al. | Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. | 2005 | Dig. Dis. Sci. | pmid:15810623 |
| Aoki D et al. | Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. | Anticancer Res. | pmid:15816530 | |
| Guna R et al. | In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. | 2005 | J. Antimicrob. Chemother. | pmid:15824090 |
| Vanderkooi OG et al. | Predicting antimicrobial resistance in invasive pneumococcal infections. | 2005 | Clin. Infect. Dis. | pmid:15825031 |
| Yuen B et al. | Cultural recovery and determination of antimicrobial susceptibility in Helicobacter pylori by using commercial transport and isolation media. | 2005 | Infection | pmid:15827875 |
| Sarihan S et al. | Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy. | 2005 | Cancer Detect. Prev. | pmid:15829379 |
| Sun WH et al. | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. | 2005 | World J. Gastroenterol. | pmid:15832421 |